Published in AIDS Weekly, December 27th, 2004
According to a study from the United States, "AMD3100 is a CXCR4 receptor inhibitor with anti-HIV-1 activity in vitro. We tested the safety, pharmacokinetics and antiviral effect of AMD3100 administered for 10 days by continuous intravenous infusion in an open-label dose escalation study front 2.5 to 160 mug/kg/hour.
"Forty HIV-infected patients with an HIV RNA level >5000 copies/ml- on stable antiretroviral (ARV) regimens or off therapy were enrolled. Syncytium-inducing (SI) phenotype in an MT-2 cell assay was required in higher dose cohorts. Most...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.